Antithrombotic activity of BM-573, a novel thromboxane modulator, in rat arterial thrombosis model, pig myocardial infarction model and its effects on bleeding time

Poster (2003, November)

Fluorine containing aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action

Poster (2003, June)

Evaluation pharmacologique et étude du mécanisme d’action de molécules structurellement apparentées au cromakalim en tant qu’activateurs des canaux KATP

Poster (2003, May)

Synthèse et évaluation biologique de nouvelles coumarines en tant qu’anticoagulants potentiels

Poster (2003, May)

Pharmacological evaluation of the thromboxane A2 receptor antagonist BM-613

Poster (2003, May)

Synthesis and pharmacological evaluation of BM-613, an original thromboxane A2 antagonist

Poster (2003, May)

Pharmacophore generation to design new leads for selective cyclooxygenase-2 (COX-2) inhibition

Poster (2003, May)

3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo

in British Journal of Cancer (2003), 88(7), 1111-1118

In search for new anticancer agents, we have evaluated the antiinvasive and antimigrative properties of recently developed synthetic coumarin derivatives among which two compounds revealed important ... [more ▼]

In search for new anticancer agents, we have evaluated the antiinvasive and antimigrative properties of recently developed synthetic coumarin derivatives among which two compounds revealed important activity: 3-chlorophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate and 3-bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate, Both drugs were able to inhibit cell invasion markedly in a Boyden chamber assay, the bromo derivative being more potent than the reference matrix metalloprotease (MMP) inhibitor GI 129471. In vivo, tumour growth was reduced when nude mice grafted with HT 1080 or MDA-MB231 cells were treated i.p. 3 days week(-1) with the bromo coumarin derivative. These effects were not associated with the inhibition of urokinase, plasmin, MMP-2 or MMP-9. The mechanism of action of the drugs remains to be elucidated. However, these two coumarin derivatives may serve as new lead compounds of an original class of antitumour agents. [less ▲]

Etude de la sélectivité tissulaire d’un nouvel antagoniste des récepteurs au thromboxane A2, le BM-613

Poster (2003, January 31)

Nouveaux composés agissant en tant que modulateurs allostériques positifs des récepteurs glutamatergiques de sous-type AMPA : les 2,3-dihydro-4H-1,2,4-benzothiadiazine 1,1-dioxydes

Poster (2003, January 31)